| Company Name: |
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
|
| Tel: |
17702719238 17702719238 |
| Email: |
sales@sun-shinechem.com |
| Products Intro: |
Product Name:LP-261
CAS:915412-67-8
Purity:98% HPLC Package:50.0mg;100.0mg; 200.0mg;500mg;1g;5g; 10g
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
| Products Intro: |
Product Name:LP-261
CAS:915412-67-8
Purity:99% HPLC Package:50Mg,100Mg,500Mg,1g,5g,10g,50g,100g,500g,1kg Remarks:XYA1265
|
LP-261 manufacturers
- LP-261
-
- $72.00 / 5mg
-
2025-05-13
- CAS:915412-67-8
- Min. Order:
- Purity: 99.76%
- Supply Ability: 10g
|
| Product Name: | LP-261 | | Synonyms: | LP-261;N-[3-(1H-indol-4-yl)-5-(2-methoxypyridine-4-carbonyl)phenyl]methanesulfonamide;NCI-H522,tubulin polymerization,tumor,SW-620,BXPC-3,H522,anti-mitotic,inhibit,LP261,MCF-7,Inhibitor,Microtubule/Tubulin,LP 261,cancer,Jurkat,LP-261;Methanesulfonamide, N-[3-(1H-indol-4-yl)-5-[(2-methoxy-4-pyridinyl)carbonyl]phenyl]-;LP-261, 10 mM in DMSO | | CAS: | 915412-67-8 | | MF: | C22H19N3O4S | | MW: | 421.47 | | EINECS: | | | Product Categories: | | | Mol File: | 915412-67-8.mol |  |
| | LP-261 Chemical Properties |
| Boiling point | 700.6±70.0 °C(Predicted) | | density | 1.391±0.06 g/cm3(Predicted) | | pka | 6.72±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | LP-261 Usage And Synthesis |
| Uses | LP-261 is a potent and orally active anti-mitotic agent and shows an inhibition of in vitro tubulin polymerization with an EC50 of 3.2 μM[1]. LP-261 inhibits growth of a human non-small-cell lung tumor (NCI-H522) in vivo and can be used for cancer research[1]. | | in vivo | LP-261 (oral gavage; 4 mg/kg; single dose) displays rapid adsorption by the oral route (Tmax=2.0 h), the terminal half-life of 1.4 h ( 0.2 h indicated a moderate rate of elimination in rat, and the volume of distribution (Vss) is 1.25 L/kg[1].LP-261 (oral gavage; 15 or 50 mg/kg; twice daily; 28 days) at 50mg/kg results in an approximately tumor volume of 130 mm3 versus 3769 mm3 in the vehicle treated group, this represents a 96% reduction in mean tumor volume. Meanwhile, LP-261 at 15 mg/kg leads to a 41% inhibition after 28 days in this mouse model[1]. | Animal Model: | Human tumor xenograft model (Injected with NCI-H522 human non-small-cell) in NCr-nu mice[1] | | Dosage: | 15 or 50 mg/kg | | Administration: | Oral gavage; 15 or 50 mg/kg; twice daily; 28 days | | Result: | Had potent anti-tumor efficacy at high dosage and exhibited no significant changes in body weights. |
| | References | [1] Rupa S Shetty, et al. Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent. J Med Chem. 2011 Jan 13;54(1):179-200 DOI:10.1021/jm100659v |
| | LP-261 Preparation Products And Raw materials |
|